{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:33:11Z","timestamp":1790800391656,"version":"4.1.0"},"reference-count":69,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["ULTR001111"],"award-info":[{"award-number":["ULTR001111"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["CHE-1337594"],"award-info":[{"award-number":["CHE-1337594"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["ULTR001111"],"award-info":[{"award-number":["ULTR001111"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P30CA016086-41"],"award-info":[{"award-number":["5P30CA016086-41"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002489"],"award-info":[{"award-number":["UL1TR002489"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0204495","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T17:44:46Z","timestamp":1538070286000},"page":"e0204495","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis"],"prefix":"10.1371","volume":"13","author":[{"given":"Stephanie A.","family":"Montgomery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen F.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip G.","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn E.","family":"Zulauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany K.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer D.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Chang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1180-0030","authenticated-orcid":true,"given":"Miriam","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"ref1","article-title":"Global tuberculosis report 2016","year":"2016"},{"key":"ref2","article-title":"Cold Spring Harb Perspect Med","volume":"5","author":"K Mdluli","year":"2015"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1586\/14760584.2016.1170599","article-title":"Why don&apos;t we have an effective tuberculosis vaccine yet?","volume":"15","author":"T Davenne","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.mib.2014.06.015","article-title":"Reactive dirty fragments: implications for tuberculosis drug discovery","volume":"21","author":"P Gopal","year":"2014","journal-title":"Curr Opin Microbiol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.drudis.2016.09.025","article-title":"Learning from the past for TB drug discovery in the future","volume":"22","author":"K Mikusova","year":"2017","journal-title":"Drug Discov Today"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2015.11.018","article-title":"Inhaled drug treatment for tuberculosis: Past progress and future prospects","volume":"240","author":"AJ Hickey","year":"2016","journal-title":"J Control Release"},{"key":"ref7","first-page":"207","article-title":"Aerosol streptomycin treatment of advanced pulmonary tuberculosis in children","volume":"80","author":"JB Miller","year":"1950","journal-title":"Am J Dis Child"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1002\/jps.23705","article-title":"Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis","volume":"102","author":"AJ Hickey","year":"2013","journal-title":"J Pharm Sci"},{"key":"ref9","author":"AJ Hickey","year":"2016"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s11095-016-1926-0","article-title":"Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy","volume":"33","author":"A Gupta","year":"2016","journal-title":"Pharm Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/dkg477","article-title":"Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis","volume":"52","author":"R Pandey","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1128\/AAC.01471-09","article-title":"Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs","volume":"54","author":"L Garcia-Contreras","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jac\/48.3.431","article-title":"Airways delivery of rifampicin microparticles for the treatment of tuberculosis","volume":"48","author":"S Suarez","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1023\/A:1013094112861","article-title":"Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model","volume":"18","author":"S Suarez","year":"2001","journal-title":"Pharm Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s11095-016-1974-5","article-title":"Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis","volume":"33","author":"EF Young","year":"2016","journal-title":"Pharm Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1128\/AAC.01164-06","article-title":"Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model","volume":"51","author":"L Garcia-Contreras","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dkh411","article-title":"Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral\/aerosolized antitubercular drug carriers for treatment of tuberculosis","volume":"54","author":"A Sharma","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nm.3458","article-title":"Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux","volume":"20","author":"RE Lee","year":"2014","journal-title":"Nat Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1128\/AAC.05633-11","article-title":"Aerosolized gentamicin reduces the burden of tuberculosis in a murine model","volume":"56","author":"CJ Roy","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1128\/AAC.02346-12","article-title":"Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis","volume":"57","author":"AS Dharmadhikari","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s11095-009-9957-4","article-title":"Inhaled drug delivery for tuberculosis therapy","volume":"26","author":"P Muttil","year":"2009","journal-title":"Pharm Res"},{"key":"ref22","first-page":"1","article-title":"Mechanisms of Pyrazinamide Action and Resistance","volume":"2","author":"Y Zhang","year":"2013","journal-title":"Microbiol Spectr"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1126\/science.1184784","article-title":"Tuberculosis: what we don&apos;t know can, and does, hurt us","volume":"328","author":"DG Russell","year":"2010","journal-title":"Science"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fimmu.2013.00098","article-title":"Modeling the <italic>Mycobacterium tuberculosis<\/italic> Granuloma\u2014the Critical Battlefield in Host Immunity and Disease","volume":"4","author":"E Guirado","year":"2013","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"V Dartois","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"B Prideaux","year":"2015","journal-title":"Nat Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1099\/0022-1317-51-1-42","article-title":"Conditions that may affect the results of susceptibility testing of <italic>Mycobacterium tuberculosis<\/italic> to pyrazinamide","volume":"51","author":"Y Zhang","year":"2002","journal-title":"J Med Microbiol"},{"key":"ref28","first-page":"317","article-title":"Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant <italic>Mycobacterium tuberculosis<\/italic>","volume":"10","author":"Y Hu","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1164\/ajrccm\/145.5.1223","article-title":"Pyrazinamide sterilizing activity in vitro against semidormant <italic>Mycobacterium tuberculosis<\/italic> bacterial populations","volume":"145","author":"L Heifets","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jac\/dkl358","article-title":"Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against <italic>Mycobacterium tuberculosis<\/italic> in vitro","volume":"58","author":"MM Wade","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1128\/MMBR.00010-14","article-title":"Latent tuberculosis infection: myths, models, and molecular mechanisms","volume":"78","author":"NK Dutta","year":"2014","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1128\/AAC.01524-10","article-title":"Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections","volume":"55","author":"Z Ahmad","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref33","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Y Zhang","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1128\/AAC.05293-11","article-title":"Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis","volume":"55","author":"R Tasneen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1128\/JCM.00973-08","article-title":"Pyrazinamide resistance among South African multidrug-resistant <italic>Mycobacterium tuberculosis<\/italic> isolates","volume":"46","author":"M Mphahlele","year":"2008","journal-title":"J Clin Microbiol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5588\/ijtld.11.0266","article-title":"Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis","volume":"16","author":"C Pierre-Audigier","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e0133869","DOI":"10.1371\/journal.pone.0133869","article-title":"A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis","volume":"10","author":"MG Whitfield","year":"2015","journal-title":"PLoS One"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/AAC.33.8.1252","article-title":"Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against <italic>Mycobacterium tuberculosis<\/italic>?","volume":"33","author":"LB Heifets","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e01819","DOI":"10.1128\/mBio.01819-14","article-title":"<italic>Mycobacterium tuberculosis<\/italic> pyrazinamide resistance determinants: a multicenter study","volume":"5","author":"P Miotto","year":"2014","journal-title":"MBio"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/AAC.00204-15","article-title":"Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in <italic>Mycobacterium tuberculosis<\/italic> clinical isolates","volume":"59","author":"SM Ramirez-Busby","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cmi.2017.03.028","article-title":"Detection of pyrazinamide resistance of <italic>Mycobacterium tuberculosis<\/italic> using nicotinamide as a surrogate","volume":"23","author":"Y Hu","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/AAC.41.3.540","article-title":"Characterization of pncA mutations in pyrazinamide-resistant <italic>Mycobacterium tuberculosis<\/italic>","volume":"41","author":"A Scorpio","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1128\/AAC.00630-11","article-title":"Pyrazinamide susceptibility testing in <italic>Mycobacterium tuberculosis<\/italic>: a systematic review with meta-analyses","volume":"55","author":"KC Chang","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tube.2010.03.005","article-title":"The near future: improving the activity of rifamycins and pyrazinamide","volume":"90","author":"DA Mitchison","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1128\/AAC.39.6.1269","article-title":"Activity of n-propyl pyrazinoate against pyrazinamide-resistant <italic>Mycobacterium tuberculosis<\/italic>: investigations into mechanism of action of and mechanism of resistance to pyrazinamide","volume":"39","author":"RJ Speirs","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1021\/jm00085a007","article-title":"Antimycobacterial activity of a series of pyrazinoic acid esters","volume":"35","author":"MH Cynamon","year":"1992","journal-title":"J Med Chem"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1128\/AAC.00936-15","article-title":"Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of <italic>Mycobacterium tuberculosis<\/italic> and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages","volume":"59","author":"D Pires","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1128\/AAC.03085-15","article-title":"High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis","volume":"60","author":"JP Lanoix","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tube.2016.04.002","article-title":"Antimycobacterial activity of pyrazinoate prodrugs in replicating and non-replicating <italic>Mycobacterium tuberculosis<\/italic>","volume":"99","author":"ND Segretti","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1021\/id500028m","article-title":"Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives","volume":"1","author":"LE Via","year":"2015","journal-title":"ACS Infect Dis"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/AAC.01369-06","article-title":"Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli","volume":"51","author":"O Zimhony","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref52","article-title":"A dry powder combination of pyrazinoic acid and its n-propyl ester for aerosol administration to animals","author":"PG Durham","year":"2016","journal-title":"Int J Pharm"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/IAI.71.2.864-871.2003","article-title":"Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with <italic>Mycobacterium tuberculosis<\/italic>","volume":"71","author":"OC Turner","year":"2003","journal-title":"Infect Immun"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0041-3879(91)90013-I","article-title":"A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment","volume":"72","author":"DW Smith","year":"1991","journal-title":"Tubercle"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.tube.2007.12.003","article-title":"Disseminated disease severity as a measure of virulence of <italic>Mycobacterium tuberculosis<\/italic> in the guinea pig model","volume":"88","author":"GS Palanisamy","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1128\/IAI.00704-09","article-title":"Kinetics of the immune response profile in guinea pigs after vaccination with <italic>Mycobacterium bovis<\/italic> BCG and infection with <italic>Mycobacterium tuberculosis<\/italic>","volume":"77","author":"A Grover","year":"2009","journal-title":"Infect Immun"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/JB.91.2.718-724.1966","article-title":"Host-parasite relationships in experimental airborne tuberculosis. I. Preliminary studies in BCG-vaccinated and nonvaccinated animals","volume":"91","author":"DW Smith","year":"1966","journal-title":"J Bacteriol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1152\/jappl.1967.22.3.453","article-title":"Scaling of respiratory variables in mammals","volume":"22","author":"WR Stahl","year":"1967","journal-title":"J Appl Physiol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology","volume":"24","author":"DE Geller","year":"2011","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1128\/AAC.00761-13","article-title":"Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen","volume":"57","author":"NK Dutta","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.40.3.552","article-title":"Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide","volume":"40","author":"J Dhillon","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1472-9792(02)00079-3","article-title":"Hematogenous reseeding of the lung in low-dose, aerosol-infected guinea pigs: unique features of the host-pathogen interface in secondary tubercles","volume":"83","author":"DN McMurray","year":"2003","journal-title":"Tuberculosis (Edinb)"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1021\/jm00020a003","article-title":"Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity","volume":"38","author":"MH Cynamon","year":"1995","journal-title":"J Med Chem"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1128\/AAC.01521-09","article-title":"Evaluation of standard chemotherapy in the guinea pig model of tuberculosis","volume":"54","author":"DJ Ordway","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/AAC.00978-10","article-title":"Activities of TMC207, rifampin, and pyrazinamide against <italic>Mycobacterium tuberculosis<\/italic> infection in guinea pigs","volume":"55","author":"S Shang","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1128\/AAC.00276-07","article-title":"Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910","volume":"51","author":"AJ Lenaerts","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"e74082","DOI":"10.1371\/journal.pone.0074082","article-title":"Host targeted activity of pyrazinamide in <italic>Mycobacterium tuberculosis<\/italic> infection","volume":"8","author":"C Manca","year":"2013","journal-title":"PLoS One"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1128\/AAC.01146-09","article-title":"The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells","volume":"53","author":"S Mendez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.chom.2012.03.008","article-title":"Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action","volume":"11","author":"JJ Kim","year":"2012","journal-title":"Cell Host Microbe"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0207257","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0204495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T06:21:28Z","timestamp":1605075688000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0204495"}},"subtitle":[],"editor":[{"given":"Ann","family":"Rawkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":69,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0204495","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0207257","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]}}}